#USA #New York #Class Action #Securities Fraud #Capricor Therapeutics

Important Update for Capricor Investors

On July 25, 2025, Levi & Korsinsky LLP alerted investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) regarding a significant class action lawsuit. This legal action seeks to address alleged securities fraud that negatively impacted shareholders between October 9, 2024, and July 10, 2025.

Class Action Overview

From October 9, 2024, to July 10, 2025, the lawsuit highlights claims that misleading information was shared about Capricor's lead drug candidate, deramiocel. This drug was intended for treating cardiomyopathy linked with Duchenne muscular dystrophy (DMD). The allegations involve the company providing overly optimistic statements regarding the FDA's review and approval process while hiding critical data about the drug's safety and efficacy.

Details of the Complaint

The complaint outlines that Capricor's management communicated confidence about receiving Biologics License Application (BLA) approval from the FDA for deramiocel. However, on July 11, 2025, the company received a Complete Response Letter (CRL) from the FDA, citing insufficient evidence to support the drug's effectiveness. This news led to a sharp decline in Capricor's stock price, dropping from $11.40 to $7.64 within a day.

What Should Investors Do?

If you suffered financial losses during this period, you have until September 15, 2025, to request the Court to appoint you as a lead plaintiff in this case. It’s crucial to note that being a lead plaintiff is not a requirement to share in any recovery that may result from the outcome of the lawsuit.

No Cost to Class Members

Investors need to understand that participating in the class action entails no out-of-pocket expenses. Eligible class members might recover losses without incurring any costs.

Why Choose Levi & Korsinsky?

For over twenty years, Levi & Korsinsky has earned a reputation for securing substantial settlements for aggrieved investors. The firm's dedication to protecting shareholder rights in complex securities litigation has earned it a spot on ISS Securities Class Action Services' Top 50 list for seven consecutive years.

If you have any questions or need assistance related to the Capricor lawsuit, you can reach out to Joseph E. Levi, Esq. at (212) 363-7500 or email him at email protected]. For more detailed information and to express your interest in joining the class action, visit their official site at [Levi & Korsinsky Website.

Conclusion

Investors in Capricor Therapeutics need to act promptly to ensure their rights are protected as the lead plaintiff deadline approaches. With professional legal guidance and support, aggrieved shareholders have an opportunity to seek the compensation they deserve. Don't miss out on the chance to be part of this critical legal action.